OKYO Pharma Limited

NasdaqCM OKYO

OKYO Pharma Limited Shareholders' Equity for the year ending March 31, 2024

OKYO Pharma Limited Shareholders' Equity is NA for the year ending March 31, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: OKYO

OKYO Pharma Limited

CEO	Dr. Gary S. Jacob Ph.D.
IPO Date	May 17, 2022
Location	United Kingdom
Headquarters	55 Park Lane
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years